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Most current articleWe evaluated the incidence of interval cancers between the first and second rounds of colo-
rectal cancer (CRC) screening with the FOB-Gold fecal immunochemical test (FIT), and the
effects of different cutoff values and patient sex and age.METHODS: We collected data from participants in a population-based CRC screening program in the
Netherlands who had a negative result from a first-round of FIT screening. We calculated the
cumulative incidence of interval cancer after a negative result froma FIT and the sensitivity of the
FIT for detection of CRC at a low (15 mg Hb/g feces) and high (47 mg Hb/g feces) cutoff value.RESULTS: Among the 485,112 participants with a negative result from a FIT, 544 interval cancers were
detected; 126were in the 111,800participantswith negative results fromaFITwith the lowcutoff
value and 418were in the 373,312 FIT participants with negative results from a FIT with the high
cutoff value. Themean age of participants testedwith the low cutoff value was 72.0 years and the
mean age of participants tested the high cutoff value was 66.7 years. The age-adjusted 2-year
cumulative incidence of interval cancer after a negative result from a FIT were 9.5 per 10,000
persons at the low cutoff value vs 13.8 per 10,000 persons at the high cutoff value (P < .005). The
age-adjusted sensitivity of the FIT for CRC were 90.5% for the low cutoff value vs 82.9% for the
high cutoff (P < .0001). The FIT identified men with CRC with 87.4% sensitivity and women with
CRC with 82.6% sensitivity (P < .001).CONCLUSIONS: In an analysis of data from a FIT population-based screening program in the Netherlands, we
found that incidence of interval CRC after a negative result from a FIT to be low. Although the
sensitivity of detection of CRC decreased with a higher FIT cutoff value, it remained above 80%.Keywords: Colon Cancer; Screening; Fecal Immunochemical Testing; Interval Cancer.rship.
r: AA, advanced adenoma; CI, confidence
er; FIT, fecal immunochemical test; Hb,
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What You Need to Know
Background
We evaluated the incidence of interval colorectal
cancer (CRC) between the first and second rounds of
screening (interval cancers) with a fecal immuno-
chemical test (FIT) and the effects of different cutoff
values, gender, and age.
Findings
In an analysis of data from the national FIT
population-based screening program in the
Netherlands, we found that incidence of interval CRC
after a negative result from an FIT to be low.
Although the sensitivity of detection of CRC
decreased with a higher FIT cutoff value, it was
above 80%.
Implications for patient care
Persons with a negative result from a screening FIT
should be tested again at the recommended interval.
1494 Toes-Zoutendijk et al Clinical Gastroenterology and Hepatology Vol. 18, No. 7Many countries have introduced a screening pro-gram for colorectal cancer (CRC) in recent years.
Different screening modalities are suitable for that pur-
pose. Opportunistic screening programs most often use
colonoscopy for primary screening, while organized
population-based programs mostly prefer fecal immuno-
chemical testing (FIT).1 Colonoscopy has better test char-
acteristics compared with FIT when applied for 1-time
screening, yet is invasive, burdensome, and costly. FIT
is noninvasive, nonburdensome, and less costly, but has
lower test sensitivity.2–4 For optimal program sensitivity
and preventive effect, FIT should be repeated regularly.
FIT has been shown to be effective in detecting CRC at
low cutoffs or short screening intervals.5,6Modeling studies
suggested that by repeating FIT annually, with an assumed
test sensitivity of 73.8% for CRC, the long-term preventive
effect would be similar to colonoscopy screening.5 The
number of interval CRCs in the Dutch CRC screening pilot
study was recently evaluated, based on 3 biennial FIT
screening rounds. This relatively small study showed an
interval CRC incidence rate of 0.1%and a sensitivity of 77%
over 3 screening rounds.6 However, these interval CRCs
were observed while using a very low FIT cutoff of 10 mg
hemoglobin (Hb)/g feces. In many regional or national
population-based organized programs a higher cutoff for a
positive FIT with referral to colonoscopy is chosen for a
better balance between true and false positives.1 Six
months after the start of the Dutch national program, the
FIT cutoff was increased from 15 to 47 mg Hb/g feces,
because of a higher than expected positivity rate with an
associated lower positive predictive value and shortage in
colonoscopy capacity.7With this higher cutoff, we assumed
that 12% of the CRCs would be missed, resulting in an
relative decrease in sensitivity of 12%.8
Evaluation of the number of interval CRCs within
organized population-based screening programs is
important. The results of the Dutch CRC FIT-based
screening program enable us to evaluate the number of
interval CRCs after the first screening and determine the
impact of using a relatively high vs a low FIT cutoff on
the cumulative incidence and sensitivity of FIT for CRC.Materials and Methods
Screening Program and Population
In the Netherlands, a national population-based CRC
screening program was implemented in 2014, with
biennial FIT screening for persons 55–75 years of age.
The program was rolled out in 5 years (2014–2018),
with a phased implementation by age groups (birth co-
horts). In 2014, individuals 60, 63, 65, 67, 75, and 76
years of age were invited. For once, also persons 76
years of age were invited in 2014, because the start of
the program was delayed. Individuals received an invi-
tation letter by postal mail including a single FIT (FOB-Gold; Sentinel Diagnostics, Milan, Italy). Participants with
a positive FIT were referred for colonoscopy. Partici-
pants with a negative result from an FIT were reinvited
24 months after the previous invitation date. Note, this is
not 24 months after a negative result from an FIT, and
therefore, there screening interval could be shorter than
2 years. At the start in 2014, the cutoff for a positive test
was defined at 15 mg Hb/g feces. As a result of a higher
than expected participation and positivity rate and a
lower than expected positive predictive value for CRC
and advanced adenomas (AAs), it was decided to in-
crease the cutoff in June 2014 to 47 mg Hb/g feces. A
more extensive description of the Dutch national CRC
screening program and the decision analysis on
increasing the cutoff was given in a previous publica-
tion.7 This current study evaluated the interval CRCs of
participants invited in the first year of the national Dutch
CRC screening program in 2014.
Outcomes
We estimated the cumulative incidence of interval
cancers and test sensitivity. The cumulative incidence
was calculated as the number of interval CRCs within 2
years after a negative result for an FIT in the first
screening round divided by the total number of in-
dividuals with a negative result from an FIT in the first
screening round. Number was presented per 10,000
individuals with a negative result from an FIT. FIT
sensitivity was approximated by the number of screen-
detected CRCs after a positive FIT in the first screening
round divided by the sum of screen-detected and interval
CRCs in the first screening round. This is a commonly
applied approximation in screening literature.
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nationally recommended nomenclature of the working
group on interval CRC of the World Endoscopy Organi-
zation.9 They designated an interval CRC as a CRC after a
negative result from an FIT but before the invitation of
subsequent screening round with FIT.
An interval CRC in this study population was defined
as follows for 2 distinct subgroups: (1) participants with
a negative result from an FIT in 2014 and eligible for
screening in the subsequent round: CRCs that occur be-
tween date of FIT analyses with negative result from an
FIT and date of invitation of the subsequent screening
round; and (2) participants with a negative result from
an FIT in 2014 and not eligible for screening in the
subsequent round because of the upper age limit: CRCs
that occur between date of FIT analyses with negative
FIT plus 24 months.
Screen-detected CRCs were defined as cancers
detected within 6 months after a positive FIT in the first
screening round.Data Collection
Data of participants with a negative result from an
FIT in 2014 were obtained from the national screening
database (ScreenIT); Hb concentration, gender, age,
invitation date, and date of analysis. All individual re-
cords of these participants were sent to the Netherlands
Cancer Registry. This registry contained information on
cancers detected in the Netherlands including data on
patients, tumor, and treatment characteristics, collected
from medical records. Linkage of participants with a
negative result from an FIT from the screening database
and the cancer registry was established by matching on
initials, birth name, family name, gender, date of birth,
postal code, place of birth, and date of death. If an indi-
vidual with a negative result from an FIT had a CRC
registered in the Netherlands Cancer Registry after the
date of the FIT analyses in 2014 and before the invitation
date of the second screening round, incidence date, and
stage (TNM classification) were collected through the
registry. To calculate the number of screen-detected
CRCs, individuals with a positive FIT in 2014 were
similarly linked with the Netherlands Cancer Registry
and equivalent data on screen-detected CRCs were
collected. All CRCs detected within 6 months after a
positive FIT were considered a screen-detected CRC. For
staging of CRCs, the seventh edition of the TNM classi-
fication was used. Carcinomas in situ were excluded from
the analyses, because these are not invasive cancers. If
individuals had more than 1 CRC diagnosed, for example
at 2 different locations, the CRC with most advanced
disease stage was selected for the analyses. The Inter-
national Classification of Diseases for Oncology was used
for coding location and was defined as rectum, rec-
tosigmoid, sigmoid, descending colon, splenic flexure,
transverse colon, hepatic flexure, ascending colon, andcecum (C18-C20).4 Left-sided colorectal cancers included
locations from rectosigmoid until descending colon and
right-sided colon cancers included locations from splenic
flexure to cecum. Appendiceal cancers were not consid-
ered a CRC in the Dutch CRC screening program.
Analysis
In all analyses the cutoff of 15 mg Hb/g feces was
referred to as low cutoff, the cutoff of 47 mg Hb/g feces
was referred to as higher cutoff. Proportions of cumu-
lative incidence and sensitivity with 95% confidence
intervals (CIs) were determined by descriptive analyses.
The different subgroups (age and gender) were
compared using the chi-square test. Because of a sub-
stantially different age distribution between the 2 cutoff
groups, we could not use the chi-square test to compare
rates by cutoff. Instead, we used the direct age stan-
dardization procedure to obtain age-adjusted rates and
multivariable logistic regression analyses to test for
statistically significant differences (P < .05) between the
2 cutoffs, adjusting for gender and age.
To also facilitate estimates for countries considering
different cutoffs than 15 or 47 mg Hb/g feces, we per-
formed an exploratory analysis to estimate the number
of interval CRCs at alternative cutoffs. For every indi-
vidual we used the absolute concentration of Hb in the
sample to determine the numbers of individuals with an
FIT positive and negative results at cutoffs of >0 mg, 10
mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg,
and 160 mg Hb/g feces and subsequently we determined
how many CRCs would have been missed at those
alternative cutoffs. This analysis was based on assump-
tion that all screen-detected CRCs would have become an
interval cancer when a cutoff below the measured fecal
Hb concentration was applied. Vice versa we assumed
that interval CRC after a negative result from an FIT of a
certain fecal Hb concentration would have been detected
by screening when that concentration was surpassed by
the cutoff.
Data analyses were performed using R version 3.5.0
(R Foundation for Statistical Computing, Vienna, Austria).
Results
In the first screening round in 2014, a total of
525,916 individuals had an assessable stool sample, of
whom 40,942 (7.8%) had a positive FIT and 484,974
(92.2%) had a negative result from an FIT. A total of
127,411 individuals were assessed with the low cutoff;
15,611 (12.3%) had a positive FIT and 111,800 (87.7%)
had a negative result from FIT. A total of 398,505 in-
dividuals were assessed with the higher cutoff: 25,331
(6.4%) had a positive FIT and 373,174 (93.6%) had a
negative result from an FIT. A total of 33,298 (81.3%) of
the FIT positive individuals had a colonoscopy follow-up.
Among those with a colonoscopy follow-up, 3210 screen-
Table 1. Characteristics of the Study Population, by Cutoff
15 mg Hb/g
Feces
(n ¼ 127,411)
47 mg Hb/g
Feces
(n ¼ 398,505)
Total
(N ¼ 525,916)
Gender
Male 60,936 (47.8) 194,537 (48.8) 255,473 (48.6)
Female 66,475 (52.2) 203.968 (51.2) 270,443 (51.4)
Age
76 y 54,961 (43.1) 19,256 (4.8) 74,217 (14.1)
75 y 25,997 (20.4) 52,204 (13.1) 78,201 (14.9)
67 y 16,103 (12.6) 124,768 (31.1) 140,871 (26.8)
65 y 28,111 (22.1) 88,340 (22.2) 116,451 (22.1)
63 y 2239 (1.8) 86,959 (21.8) 89,198 (17.0)
60 y — 26,978 (6.8) 26,978 (5.1)
FIT negative 111,800 (87.7) 373,174 (93.69) 484,974 (92.2)
FIT positivea 15,611 (12.3) 25,331 (6.4) 40,942 (7.8)
Screen-detected
CRCs
1102 (0.9) 2108 (0.5) 3210 (0.6)
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and 2108 with a high cutoff (Table 1). Among those with
a negative result from an FIT, 544 interval CRCs were
detected, 126 interval CRCs using the low cutoff and 418
interval CRC using the higher cutoff. Mean age of in-
dividuals tested at the low cutoff was 72.0 years and at
the higher cutoff was 66.7 years. Median follow-up time
between negative result from an FIT and end of interval
(invitation subsequent screening round of 24 months for
those over 75 years of age) was 730 (interquartile range,
726–730) days. Median follow-up time between negative
result from an FIT and date of interval CRC was 469
(interquartile range, 283–618) days. Of all interval CRCs,
188 (34.6%) were detected in the first year after a
negative result from an FIT and 356 (64.4%) were
detected in the second year after a negative result from
an FIT.Interval CRCs 126 (0.1) 418 (0.1) 544 (0.1)
Values are n (%).
CRC, colorectal cancer; FIT, fecal immunochemical testing.
aDefined as a value at or above the cutoff of 15 or 47 mg Hb/g feces.Cumulative Incidence
The cumulative incidence of interval CRC after a
negative result from an FIT in the first screening round
was 11.2 (95% CI, 10.3–12.2) per 10,000 individuals
(Table 2). The cumulative incidence for men of 12.2
(95% CI, 10.9–13.7) per 10,000 individuals was slightly
higher than the cumulative incidence for women of 10.3
(95% CI, 9.2–11.6) per 10,000 individuals, but just not
significantly different (p ¼ .06). Cumulative incidence
significantly increased with age (Figure 1) (p < .001).
Note, only selected age groups were invited. After
adjusting for age differences, the cumulative incidence of
interval CRCs was 9.5 per 10,000 individuals at the low
cutoff vs 13.8 per 10,000 individuals at the higher cutoff.
Multivariable logistic regression analysis showed a sig-
nificant difference between the 2 cutoffs, after adjusting
for gender and age (p ¼ .0005).Sensitivity
Average sensitivity for CRC over both cutoffs in the
first screening round was 85.5% (95% CI, 84.3%–
86.6%). The sensitivity of 87.4% (95% CI, 86.0%–88.7%)
among men was higher than the sensitivity of 82.6%
(95% CI, 80.6%–84.5%) among women (p <.001).
Sensitivity was not significantly different by age
(Figure 2) (p ¼ .52). Age-adjusted sensitivity at the low
cutoff was 90.5% and 82.9% at the higher cutoff.
Multivariable logistic regression analysis showed a sig-
nificant difference between the 2 cutoffs, after adjusting
for gender and age (p < .0001).
Exploratory analysis across the full range of relevant
cutoffs showed the expected inverse correlation between
cutoff and interval CRC rate, with a marked increase in
interval CRC rate at high cutoffs (Figure 3). Largest
decrease (1.3%–0.5%) in positivity rate was observed at
low cutoffs (above 0 up to 80 mg Hb/g feces). Above 80
mg Hb/g feces, an approximately 0.3% decrease inpositivity rate was observed per 10 mg Hb/g feces in-
crease of FIT cutoff. Contrary, largest decrease in FIT
sensitivity for CRC was observed at high cutoffs. FIT
sensitivity drops below 70% with cutoffs higher than 90
mg Hb/g feces, with a sensitivity of only 52.0% at the FIT
cutoff 160 mg Hb/g feces.
Stage Distribution and Location
A total of 93 (19.8%) stage I, 82 (17.5%) stage II, 175
(37.2%) stage III, and 120 (25.5%) stage IV interval CRCs
were detected. For 74 (15.7%) interval CRCs, stage was
unknown. There was no difference between the low
cutoff with 75 (63.0%) interval CRCs and the high cutoff
with 220 (62.7%) interval CRCs in a late stage (stage III
and IV; p ¼ .84). A total of 269 (52.5%) of the interval
CRCs were located on the right side, 106 (20.5%) were
located on the left side, and 141 (27.3%) were located at
the rectum. At the low cutoff, a larger proportion of the
interval CRCs (119 [57.1%]) were detected on the
right-side compared with the higher cutoff (397 [50.6%])
(p ¼ .92)
Discussion
In the first screening round of a national FIT-based
CRC screening program, a low incidence of interval
CRC in the 2 years after a negative result from an FIT was
observed, irrespective of cutoff. This supports the high
FIT sensitivity for CRC. However, the cumulative inci-
dence of interval CRC was higher and sensitivity was
lower for individuals tested with the higher cutoff. Older
age was associated with a higher interval CRC incidence
and FIT sensitivity was lower for women than for men.
Table 2. Screen-Detected and Interval Cancers, Cumulative Incidence and Sensitivity Using 2 Cutoffs
Negative
FITs
Screen-
detected
CRCs
Interval
CRCs
Cumulative incidence
per 10,000
individuals
(95% CI)a
Sensitivity
(95% CI) (%)b
Total
All 484,974 3200 544 11.2 (10.3–12.2) 85.5 (84.3–86.6)
Men 231,138 1964 282 12.2 (10.9–13.7) 87.4 (86.0–88.7)
Women 253,836 1246 262 10.3 (9.2–11.6) 82.6 (80.6–84.5)
Cutoff 15 mg Hb/g feces
All 111,800 1102 126 11.3 (9.5–13.4) 89.7 (87.9–91.3)
Age adjusted 9.5 90.5
Men 52,025 656 73 14.0 (11.1–17.7) 90.0 (87.6–92.0)
Women 59,775 446 53 8.9 (6.8–11.6) 89.4 (86.4–91.8)
Cutoff 47 mg Hb/g feces
All 373,174 2108 418 11.2 (10.2–12.3) 83.5 (82.0–84.9)
Age adjusted 13.8 82.9
Men 179,113 1308 209 11.7 (10.2–13.4) 86.2 (84.4–87.9)
Women 194,061 800 209 10.8 (9.4–12.3) 79.3 (76.7–81.7)
CI, confidence interval; CRC, colorectal cancer; FIT, fecal immunochemical testing.
aCumulative incidence is the number of interval CRCs after a negative FIT per 10,000 individuals with a negative FIT.
bSensitivity is the number of screen-detected CRCs after a positive FIT divided by the total number of CRCs (screen-detected CRCs and interval CRCs).
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CRCs because of a high FIT sensitivity for CRC. Our
estimated risk of CRC diagnosis after a negative result
from an FIT is approximately 5-fold lower compared
with the risk in a similar population before the intro-
duction of CRC screening.10 The sensitivity in the first
screening round for both cutoffs (90.5% and 82.9%) was
higher than anticipated (77%), based on the Dutch pilot
studies preceding the national program.6 There are 3
potential explanations for this. First, the stability of the
buffer of the FIT has been improved, Consequently,
higher FIT cutoffs result in similar sensitivity for CRC as
lower FIT cutoffs in the past. Second, the median interval
between screening rounds was longer in the pilot studyFigure 1. Cumulative inci-
dence (number of interval
colorectal cancers after a
negative fecal immuno-
chemical testing [FIT] per
10,000 individuals with a
negative FIT) of interval
colorectal cancer with
95% confidence interval
after negative FIT.(2.4 years) compared with our study (2.0 years).6 A
longer interval could result in more interval CRCs and
therefore may have decreased the sensitivity. However,
the third, and most important, explanation is that we
estimated the sensitivity in the first screening round of
the national program, which is a prevalent screening
round, while the sensitivity of the pilot study was
derived from the total of 3 screening rounds. In the first
screening round, relatively more screen-detected CRCs
will be detected than in subsequent screening rounds,
but the interval CRCs will remain stable; therefore, the
sensitivity is likely to decrease in subsequent screening
rounds. We approximated the FIT sensitivity using
screen-detected and interval CRCs, because the real
Figure 2. Fecal immuno-
chemical testing sensitivity
(number of screen-
detected colorectal can-
cers [CRCs] after a posi-
tive fecal immunochemical
testing divided by the total
number of CRCs [screen-
detected CRCs and inter-
val CRCs]) with 95%
confidence interval for
colorectal cancer.
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screening is unknown. This approximation has 3 biases.
First, sensitivity may be overestimated, because not all
missed CRCs will have developed into interval CRCs
within 2 years. This hypothesis is in line with a recent
systematic review, with all individuals having a colo-
noscopy follow-up after 1-time only FIT, showing an FIT
sensitivity for CRC of 71%.4 Second, some interval CRCs
included in the definition of the sensitivity may not have
been a missed screen-detected CRC, but still an AA at
previous screening. This might lead to an underestima-
tion of the sensitivity. Third, deaths before the end of the
interval may have resulted in an overestimation of the
sensitivity.
Our estimated FIT sensitivities are at the higher end
of those observed in literature.11–14 However, the Kaiser
Permanente group also reported a sensitivity of 85% in
the first screening round and then showed a decrease in
sensitivity of 6%–8% in subsequent screening rounds.Figure 3. Positivity rate (defined as the number of participants w
participants with an assessable stool sample) and fecal imm
colorectal cancers [CRCs] after a positive fecal immunochem
detected CRCs and interval CRCs]) for colorectal cancer at a rConsequently, the sensitivity over 4 screening rounds
was approximately 80%.11 It is therefore expected that
our sensitivity will also decrease in subsequent
screening rounds, and will not be that different from the
77% reported in the Dutch pilot studies.6
We observed differences between the age-adjusted
cumulative incidence and sensitivity between the low
and higher FIT cutoffs. Despite this difference, the cu-
mulative incidence with the higher cutoff was still low,
with 13.8 per 10,000 individuals, and more than 4 of 5
CRCs will be detected in the first screening round. Also,
our a priori expectation was that with a higher cutoff the
sensitivity would decrease with 12%. However, the
observed decrease of 7.6% in this study was surprisingly
smaller.8 The exploratory analysis across the full range of
relevant cutoffs showed an increase in interval CRC rate
at high FIT cutoffs, which is in line with our main finding.
With high FIT cutoffs (160 mg Hb/g feces) half of the
CRCs will probably be missed.ith a test result at or above the cutoff divided by the number of
unochemical testing sensitivity (number of screen-detected
ical testing divided by the total number of CRCs [screen-
ange of cutoffs
June 2020 Incidence of Interval CRC after Negative Results From FIT 1499The sensitivity for CRC with the higher cutoff was in
line with findings of the aforementioned Dutch pilot
studies using a cutoff of 10 mg Hb/g feces and the Kaiser
Permanente group using a cutoff of 20 mg Hb/g feces.6,11
Again, this confirms that the performance of FIT with the
old buffer using a low cutoff is comparable to the FIT,
with the new buffer using a higher cutoff. In a recent
systematic review, no difference in sensitivity was
observed between different cutoffs, but most included
studies used a relatively low cutoff (10–20 mg Hb/g
feces). Nevertheless, the high sensitivity for CRC with a
higher cutoff in the current study is promising for many
organized programs using high FIT cutoffs.15 The results
of this study were based on FOB-Gold screening, but we
do expect that they will be generalizable to other FIT
brands as a recent study showed comparable perfor-
mance of FOB-Gold and OC-Senso (Eiken, Japan).16
Noteworthy is the difference between the results of the
higher cutoffs with FIT in this study compared with
sensitivity of guaiac fecal occult blood testing of 67.1%.17
Our results confirm the higher FIT sensitivity for
men than for women.6,13,14,18 This might raise the
question whether different screening strategies for
men and women should be applied. However, a deci-
sion analysis has shown that risk stratification by
gender is currently not effective.19 We were unable to
demonstrate that FIT sensitivity differed by age. This is
contrary to other findings suggesting a different
sensitivity by age, although the studies presented
conflicting results. The increased cumulative incidence
for an interval CRC by age can be explained by the
higher risk of having a CRC or AA at older age.13,14,20,21
The stage distribution and location of the interval CRCs
were similar for both cutoffs. Interestingly, the stage
distribution of interval CRCs is comparable to the stage
distribution of clinically detected CRCs, indicating that
there probably is no false reassurance after receiving a
negative result from an FIT. In contrast, location of the
interval CRC is substantially different from that of
CRCs detected after symptoms, with many more right-
sided interval CRCs, suggesting a lower FIT sensitivity
for right-sided CRCs.22
The major strength of this study is the opportunity of
comparing 2 FIT cutoffs, applied in the same population
within an organized CRC screening program. We ob-
tained valuable information on the impact of using a
higher cutoff. Another strength is the large sample size,
using data of a national screening program. A limitation
of the study is that we could not estimate sensitivity for
AAs. AAs are mostly asymptomatic and therefore not
picked up between screenings, and even then not regis-
tered at the cancer registry. A recent systematic review
showed lower FIT sensitivity for AA than for CRC for 1-
time testing only.4,5 However, we expect that missed AAs
will be detected with repeated FIT in subsequent
screening rounds, as AAs or an early CRC. Another lim-
itation is that the current conclusions can only be based
on the results of selected age groups, due to a phasedimplementation by birth cohort. Now that the full
screening program has been implemented, we will assess
interval CRCs of all age groups and interval CRCs of
subsequent screening rounds.
In conclusion, the incidence of interval CRC after a
negative result from FIT is low. Although FIT sensitivity
for CRC declined with a higher cutoff, it remained above
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